Myeloperoxidase: Growing importance in cancer pathogenesis and potential drug target.


Journal

Pharmacology & therapeutics
ISSN: 1879-016X
Titre abrégé: Pharmacol Ther
Pays: England
ID NLM: 7905840

Informations de publication

Date de publication:
08 2022
Historique:
received: 02 08 2021
revised: 24 11 2021
accepted: 02 12 2021
pubmed: 11 12 2021
medline: 20 7 2022
entrez: 10 12 2021
Statut: ppublish

Résumé

Myeloperoxidase is a heme-peroxidase which makes up approximately 5% of the total dry cell weight of neutrophils where it is predominantly found in the primary (azurophilic) granules. Other cell types, such as monocytes and certain macrophage subpopulations also contain myeloperoxidase, but to a much lesser extent. Initially, the function of myeloperoxidase had been mainly associated with its ability as a catalyzer of reactive oxidants that help to clear pathogens. However, over the past years non-canonical functions of myeloperoxidase have been described both in health and disease. Attention has been specially focused on inflammatory diseases, in which an exacerbate infiltration of leukocytes can favor a poorly-controlled production and release of myeloperoxidase and its oxidants. There is compelling evidence that myeloperoxidase derived oxidants contribute to tissue damage and the development and propagation of acute and chronic vascular inflammation. Recently, neutrophils have attracted much attention within the large diversity of innate immune cells that are part of the tumor microenvironment. In particular, neutrophil-derived myeloperoxidase may play an important role in cancer development and progression. This review article aims to provide a comprehensive overview of the roles of myeloperoxidase in the development and progression of cancer. We propose future research approaches and explore prospects of inhibiting myeloperoxidase as a strategy to fight against cancer.

Identifiants

pubmed: 34890688
pii: S0163-7258(21)00254-0
doi: 10.1016/j.pharmthera.2021.108052
pii:
doi:

Substances chimiques

Oxidants 0
Peroxidase EC 1.11.1.7

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

108052

Subventions

Organisme : Austrian Science Fund FWF
ID : DOC 31
Pays : Austria

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest All authors declare that there are no conflicts of interest

Auteurs

Paulina Valadez-Cosmes (P)

Otto Loewi Research Center, Division of Pharmacology, Medical University of Graz, Graz, Austria.

Sofia Raftopoulou (S)

Otto Loewi Research Center, Division of Pharmacology, Medical University of Graz, Graz, Austria.

Zala Nikita Mihalic (ZN)

Otto Loewi Research Center, Division of Pharmacology, Medical University of Graz, Graz, Austria.

Gunther Marsche (G)

Otto Loewi Research Center, Division of Pharmacology, Medical University of Graz, Graz, Austria.

Julia Kargl (J)

Otto Loewi Research Center, Division of Pharmacology, Medical University of Graz, Graz, Austria. Electronic address: julia.kargl@medunigraz.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH